X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-13 | DNTH | Dianthus Therapeutics, Inc. /De/ | Randhawa Simrat | EVP, Head of R, D | S - Sale+OE | $37.55 | -196,538 | 4,000 | -98% | -$7,379,887 | |||||
| D | 2025-11-12 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $65.07 | -20,000 | 958,761 | -2% | -$1,301,410 | |||||
| D | 2025-11-12 | CRWV | Coreweave, Inc. | Venturo Brian M | Chief Strategy Officer | S - Sale+OE | $87.57 | -281,250 | 668,694 | -30% | -$24,630,107 | |||||
2025-11-14 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $65.00 | -2,000 | 197,871 | -1% | -$130,000 | ||||||
2025-11-14 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $11.18 | -15,485 | 225,454 | -6% | -$173,074 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |